Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Med. 2020 Nov;9(22):8650-8661. doi: 10.1002/cam4.3474. Epub 2020 Oct 5.
Elevated serum lactate dehydrogenase (sLDH) is associated with poor clinical outcomes in patients with stage IV metastatic melanoma (MM). It is currently unknown if sLDH elevation correlates with distinct molecular, metabolic, or immune features of melanoma metastases. The identification of such features may identify rational therapeutic strategies for patients with elevated sLDH. Thus, we obtained sLDH levels for melanoma patients with metastases who had undergone molecular and/or immune profiling. Our analysis of multi-omics data from independent cohorts of melanoma metastases showed that elevated sLDH was not significantly associated with differences in immune cell infiltrate, point mutations, DNA copy number variations, promoter methylation, RNA expression, or protein expression in melanoma metastases. The only significant association observed for elevated sLDH was with the number of metastatic sites of disease. Our data support that sLDH correlates with disease burden, but not specific molecular or immunological phenotypes, in metastatic melanoma.
血清乳酸脱氢酶（sLDH）升高与 IV 期转移性黑色素瘤（MM）患者的临床预后不良相关。目前尚不清楚 sLDH 升高是否与黑色素瘤转移的不同分子、代谢或免疫特征相关。如果能识别出这些特征，可能会为 sLDH 升高的患者确定合理的治疗策略。因此，我们对接受了分子和/或免疫特征分析的转移性黑色素瘤患者的 sLDH 水平进行了检测。我们对来自黑色素瘤转移的独立队列的多组学数据进行了分析，结果表明，sLDH 升高与黑色素瘤转移中的免疫细胞浸润、点突变、DNA 拷贝数变异、启动子甲基化、RNA 表达或蛋白表达无显著差异。唯一观察到与 sLDH 升高显著相关的是疾病转移部位的数量。我们的数据支持 sLDH 与转移性黑色素瘤的疾病负担相关，但与特定的分子或免疫表型无关。
